Elafibranor and Choosing Amongst PPAR Agonists in PBC
December 11th 2024The panel of experts examine the long-term data for the recently FDA-approved PPAR-δ agonist elafibranor in the treatment of primary biliary cholangitis (PBC), comparing its clinical findings with those of seladelpar, and explores how to choose the right peroxisome proliferator-activated receptor (PPAR) agonist and assess treatment effectiveness.
Read More
Pruritus Control With PPAR Agonists in PBC
December 11th 2024The panel of experts discuss the role of effectively treating pruritus, a common and debilitating symptom in over 80% of patients with cholestatic liver diseases like primary biliary cholangitis (PBC), and its importance in the long-term management of the disease.
Read More
PPAR Agonists for Treatment of PBC
December 4th 2024The panel of experts explore the use of FDA-approved peroxisome proliferator-activated receptor (PPAR) agonists in the management of primary biliary cholangitis (PBC), discussing their scientific basis, how they differ from fibrates, and their role in combination with ursodeoxycholic acid (UDCA) or as monotherapy for UDCA-intolerant patients.
Read More
Second-Line Treatments and Management of Symptoms in PBC
November 27th 2024The panel of experts cover second-line treatment options for primary biliary cholangitis (PBC), focusing on the use of obeticholic acid (OCA), its mechanism of action, management of adverse effects like pruritus and fatigue, the role of off-label fibrates, and strategies for assessing and adjusting therapy based on patient response and adverse effects.
Read More
Treatment Goals and First-Line Therapy in PBC
November 27th 2024The panel of experts outline the primary treatment goals for patients with primary biliary cholangitis (PBC), detailing how goals adjust based on disease severity, the role of ursodeoxycholic acid (UDCA) as first-line therapy, and the challenges that may require therapy modifications based on biochemical response.
Read More
Disease Progression and Extrahepatic Manifestations of PBC
November 20th 2024The panel of experts examine major complications and comorbidities associated with primary biliary cholangitis (PBC), including vitamin deficiencies, osteoporosis, and conditions like metabolic-associated steatohepatitis (MASH), autoimmune disorders, and obesity.
Read More
Considerations for Treatment Sequencing in Primary Biliary Cholangitis
August 15th 2024In this video segment, Reau, Trivedi, and Hirschfield discuss how treatment sequencing in PBC has evolved over time with the emergence of new second-line therapies and considerations for determining sequencing.
Read More
Assessing PBC Treatment Options, Determining Sequencing
August 15th 2024In this video segment, Reau, Trivedi, and Hirschfield discuss the EMA opinion on obeticholic acid and its impact on discussions about second-line therapies amid the influx of new treatment options available for patients.
Read More
Practical Tips for the Primary Care Clinician Treating HE
Published: July 15th 2024 | Updated: July 15th 2024The group of hepatic encephalopathy (HE) professionals acknowledges the challenges and potential overwhelm faced by busy primary care practices when managing patients with HE, and they provide practical clinical pearls and advice to support these clinicians in delivering effective care and improving patient outcomes.
Read More
Managing Adverse Effects in HE Treatment
Published: July 8th 2024 | Updated: July 9th 2024Medical experts discuss the management of patients with hepatic encephalopathy (HE) receiving lactulose and rifaximin therapy and develop diarrhea or a urinary tract infection (UTI) in the outpatient setting.
Read More
AASLD Guidelines for Hepatic Encephalopathy: Rifaximin's Role and Safety
July 2nd 2024The panel reviews the current American Association for the Study of Liver Diseases (AASLD) guideline recommendations for treating patients with hepatic encephalopathy (HE), and they also discuss the role of rifaximin, its ability to be prescribed by primary care clinicians, and its safety profile.
Read More
Current Hepatic Encephalopathy Therapies Targeting Gut-Liver Axis Disturbance
July 2nd 2024Nancy Reau, MD, leads a discussion on the current abnormality-targeting agents used to prevent and treat hepatic encephalopathy (HE) by addressing the gut-liver axis, specifically focusing on lactulose or lactitol and rifaximin, while also explaining their mechanisms of action and adverse event profiles.
Read More
Hepatic Encephalopathy: Exploring Alterations in Microbiota Caused by Liver Disease
June 25th 2024Kimberly Brown, MD, explains the role of the gut microbiota in the development of hepatic encephalopathy (HE) and describes the common alterations to the microbiota that occur because of chronic liver disease.
Read More
Preventing Cirrhosis Progression: Gut-Liver Axis, Circulation, Inflammation
June 25th 2024Arun B. Jesudian, MD, discusses strategies to prevent the progression of cirrhosis, which include targeting microbiome abnormalities to improve the gut-liver axis, enhancing circulatory function, treating the inflammatory state, and addressing portal hypertension.
Read More
Collaborating with Specialists: Primary Care Clinician’s Evolving Role in HE Management
June 18th 2024The panel examines the evolving role of primary care clinicians in managing patients with hepatic encephalopathy (HE) and emphasizes the importance of consulting specialists when necessary, providing insights from the perspective of a primary care clinician.
Read More
HE Experts on Symptoms, Risk Factors, Diagnosis Challenges, and Severity Grading
June 18th 2024The expert panelists explore the symptoms and risk factors associated with HE, the challenges in diagnosing the condition due to its resemblance to neuropsychiatric l disorders, and the methods used to assess and grade the severity of the disease.
Read More
Educating Primary Care Clinicians on Outpatient HE Management and Ammonia Testing
June 11th 2024Medical experts emphasize the importance of educating primary care clinicians about the outpatient management of hepatic encephalopathy, a common complication of portal hypertension, and highlight the crucial role of ammonia testing in effectively managing the disease.
Read More
Exploring the Impact of Hepatic Encephalopathy on Patients and Their Families
June 11th 2024Pamela Kushner, MD, FAAFP; Nancy Reau, MD; Arun B. Jesudian, MD, and Kimberly Brown, MD, discuss the impact of hepatic encephalopathy (HE) on patients and their families, as well as strategies for improving patient outcomes.
Read More